Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 ...

as a foundational component for advancing the development of next-generation T cell engager (TCE) bispecific and multi-specific antibodies. This format offers a unique combination of potency ...

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.39%, which has investors questioning if this is right time to ...

(Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced ...